⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409078 | 0.78 | APLNR (0.33) | — | |
| SCHEMBL9275776 | 0.77 | APLNR (0.30) | — | |
| SCHEMBL16593423 | 0.77 | VDR (0.32) | — | |
| SCHEMBL30140405 | 0.76 | — | — | |
| SCHEMBL275290 | 0.74 | — | — | |
| SCHEMBL28557302 | 0.73 | USP2 (0.30) | — | |
| SCHEMBL21801551 | 0.73 | — | — | |
| SCHEMBL19986236 | 0.73 | — | — | |
| SCHEMBL26845347 | 0.73 | — | — | |
| SCHEMBL11053602 | 0.73 | GAA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2025-01-23 | — | — | US | disclosed |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2024-10-01 | — | — | US | disclosed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| WO-2024083208-A1 | KIF18A PROTEIN INHIBITOR | 杭州邦顺制药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117917405-A | KIF18A protein inhibitors | 杭州邦顺制药有限公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-4347580-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794918-A | Substituted tetrahydrofuran analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4288426-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | Black Diamond Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117203202-A | Quinoxaline derivative and use thereof | 黑钻治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117062811-A | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and medical use thereof | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| WO-2022254362-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF | NOVARTIS AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| CN-115176005-A | Compositions and methods for treating hemoglobinopathies | 诺华股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022170122-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-114828959-A | 3- (5-methoxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |